SLC35A2 and gastric adenocarcinoma: To sum up, these results obviously demonstrated a significantly relation of the higher SLC35A2 expression with the worse outcomes in STAD patients, and that SLC35A2 might serve as an independent prognostic biomarker in STAD patients.